Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems
暂无分享,去创建一个
[1] C. Newberry,et al. Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician’s Guide , 2021, Current Gastroenterology Reports.
[2] Yulin Xiang,et al. Effect of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis , 2021, Frontiers in Nutrition.
[3] R. Moreau,et al. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. , 2021, Journal of hepatology.
[4] C. Datz,et al. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease , 2021, Hepatology International.
[5] N. Méndez-Sánchez,et al. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases , 2021, Journal of clinical and translational hepatology.
[6] A. Israni,et al. OPTN/SRTR 2019 Annual Data Report: Liver , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] S. Terai,et al. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database , 2021, Journal of Gastroenterology.
[8] A. Dhawan,et al. NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.
[9] A. Majumdar,et al. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation , 2020, World journal of hepatology.
[10] R. Moreau,et al. The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. , 2020, Journal of hepatology.
[11] P. Bork,et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure , 2020, Nature Reviews Gastroenterology & Hepatology.
[12] M. Silva,et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. , 2020, The lancet. Gastroenterology & hepatology.
[13] Praveen Sharma,et al. Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. , 2020, Translational gastroenterology and hepatology.
[14] N. Mahmud,et al. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality , 2020, Hepatology.
[15] N. Borruel,et al. ALTERATIONS IN GUT MICROBIOME IN CIRRHOSIS AS ASSESSED BY QUANTITATIVE METAGENOMICS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE AND PROGNOSIS. , 2020, Gastroenterology.
[16] A. Canbay,et al. Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease , 2020, Alimentary pharmacology & therapeutics.
[17] S. Shreay,et al. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database , 2020, EClinicalMedicine.
[18] F. Bonomini,et al. Cold Press Pomegranate Seed Oil Attenuates Dietary-Obesity Induced Hepatic Steatosis and Fibrosis through Antioxidant and Mitochondrial Pathways in Obese Mice , 2020, International journal of molecular sciences.
[19] P. Thuluvath,et al. Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. , 2020, Translational gastroenterology and hepatology.
[20] S. Wen,et al. Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis , 2020, Scientific Reports.
[21] S. Greenberg,et al. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States , 2020, Journal of clinical and translational hepatology.
[22] Suying Li,et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data , 2020, Alimentary pharmacology & therapeutics.
[23] R. Moreau,et al. Liver Transplantation for Acute‐on‐Chronic Liver Failure: Science or Fiction? , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[24] N. Chavez-Tapia,et al. Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease , 2020, Annals of Hepatology.
[25] M. Moriguchi,et al. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non‐alcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[26] S. Bollipo,et al. What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[27] S. Taneja,et al. Nonalcoholic steatohepatitis recurrence after liver transplant. , 2020, Translational gastroenterology and hepatology.
[28] C. Moylan,et al. Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C , 2020, Transplantation.
[29] M. Siddiqui,et al. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. , 2020, Gastroenterology clinics of North America.
[30] L. Henry,et al. Epidemiology of Non-alcoholic Fatty Liver Disease in North America. , 2020, Current pharmaceutical design.
[31] A. Sanyal,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.
[32] Rizwan Ahamed,et al. Acute exacerbated severe form of nonalcoholic steatohepatitis leading to acute-on-chronic liver failure: A case series , 2020, Indian Journal of Gastroenterology.
[33] C. Byrne,et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. , 2020, Metabolism: clinical and experimental.
[34] S. Satapathy,et al. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . , 2020, Translational gastroenterology and hepatology.
[35] R. de Cabo,et al. Effects of Intermittent Fasting on Health, Aging, and Disease. , 2019, The New England journal of medicine.
[36] R. Mookerjee,et al. Acute-on-chronic liver failure: definition, prognosis and management , 2019, Frontline Gastroenterology.
[37] Lanjuan Li,et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis , 2019, Scientific Reports.
[38] P. Kamath,et al. Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease. , 2019, Translational gastroenterology and hepatology.
[39] K. Szászi,et al. Claudin-2: Roles beyond Permeability Functions , 2019, International journal of molecular sciences.
[40] L. Henry,et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease , 2019, Hepatology International.
[41] Monica A. Tincopa,et al. Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post Liver Transplant: Systematic Review and Meta-analysis. , 2019, Transplantation.
[42] M. Berenguer,et al. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. , 2019, Annals of hepatology.
[43] J. Hodson,et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.
[44] Yuan He,et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.
[45] Y. Chawla,et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update , 2019, Hepatology International.
[46] R. Vettor,et al. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease , 2019, International journal of molecular sciences.
[47] P. Kamath,et al. NASH Is the Most Rapidly Growing Etiology for Acute‐on‐Chronic Liver Failure‐Related Hospitalization and Disease Burden in the United States: A Population‐Based Study , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[48] Zhaohan Wang,et al. Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. , 2019, Clinics and research in hepatology and gastroenterology.
[49] F. Larsen. Artificial liver support in acute and acute-on-chronic liver failure , 2019, Current opinion in critical care.
[50] H. El‐Serag,et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. , 2019, Journal of hepatology.
[51] K. Reddy,et al. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[52] B. Ericzon,et al. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation , 2019, Scandinavian journal of gastroenterology.
[53] N. Selzner,et al. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[54] M. Laryea,et al. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. , 2019, Transplantation.
[55] G. Marchesini,et al. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. , 2019, Transplantation.
[56] G. Svegliati-Baroni,et al. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.
[57] A. Panduro,et al. Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions , 2018, World journal of clinical cases.
[58] K. Tsuneyama,et al. Gut microbiota translocation promotes autoimmune cholangitis. , 2018, Journal of autoimmunity.
[59] M. Manns,et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.
[60] P. Kamath,et al. Grand Rounds: Alcoholic Hepatitis. , 2018, Journal of hepatology.
[61] J. Trebicka,et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.
[62] Wesley J. Marrero,et al. Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States , 2019, Hepatology.
[63] M. A. Khan,et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.
[64] Y. Chawla,et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models , 2017, Hepatology International.
[65] A. Sanyal,et al. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis , 2017, Transplantation.
[66] A. McCullough,et al. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation , 2017, European journal of gastroenterology & hepatology.
[67] E. Gorospe,et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. , 2017, Gastroenterology.
[68] R. Moreau,et al. Acute-on-chronic liver failure: an update , 2017, Gut.
[69] P. Kamath,et al. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States , 2016, Hepatology.
[70] P. Wilmes,et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility , 2016, Cell.
[71] Robert Blissett,et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.
[72] P. Kamath,et al. Acute-on-chronic liver failure in cirrhosis , 2016, Nature Reviews Disease Primers.
[73] A. Diehl,et al. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. , 2016, Clinics in liver disease.
[74] L. Adams,et al. International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .
[75] X. Qi,et al. Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure , 2016, Expert review of gastroenterology & hepatology.
[76] C. Moylan,et al. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation , 2016, Digestive Diseases and Sciences.
[77] Yi Shen,et al. Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure , 2016, Medicine.
[78] I. Bergheim,et al. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. , 2015, The Journal of nutritional biochemistry.
[79] A. de Gottardi,et al. Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis , 2015, Hepatology.
[80] S. Rensen,et al. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation , 2015, Hepatology International.
[81] C. Streba,et al. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. , 2015, World journal of gastroenterology.
[82] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.
[83] H. Yoshiji,et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model , 2014, Molecular medicine reports.
[84] G. Szabo. Gut-liver axis in alcoholic liver disease. , 2015, Gastroenterology.
[85] N. Milić,et al. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. , 2014, World journal of gastroenterology.
[86] J. Dumortier,et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[87] Donghee Kim,et al. Epidemiology of Nonalcoholic Fatty Liver Disease , 2014 .
[88] N. Chavez-Tapia,et al. The prevalence of nonalcoholic fatty liver disease in the Americas. , 2014, Annals of hepatology.
[89] E. Elamin,et al. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[90] R. Moreau,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.
[91] Lixin Zhu,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.
[92] N. Chavez-Tapia,et al. Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. , 2013, Annals of hepatology.
[93] P. Kamath,et al. Acute-on chronic liver failure. , 2012, Journal of hepatology.
[94] C. Vagianos,et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability , 2012, European journal of clinical investigation.
[95] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[96] K. Reddy,et al. Immune dysfunction and infections in patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[97] Baoli Zhu,et al. Characterization of fecal microbial communities in patients with liver cirrhosis , 2011, Hepatology.
[98] B. Nemes,et al. Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis. , 2011, Transplantation proceedings.
[99] G. Klintmalm,et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[100] P. Portincasa,et al. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[101] N. Chavez-Tapia,et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. , 2005, Annals of hepatology.
[102] M. Uribe,et al. Etiology of liver cirrhosis in Mexico. , 2004, Annals of hepatology.
[103] J. Aparicio,et al. Intestinal permeability is increased in patients with advanced cirrhosis. , 2003, Hepato-gastroenterology.
[104] G. Jacquemin. [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.
[105] M. Dumont,et al. European Association for the Study of the Liver , 1971 .